论文部分内容阅读
目的本研究旨在观察曲美他嗪治疗缺血性心肌病心力衰竭的近期疗效(4周)。方法本试验为随机、开放、对照临床研究。从入院患者中选择缺血性心肌病心力衰竭患者82例,随机分为常规治疗组(41例)和曲美他嗪组(41例),分别给予常规治疗和加用曲美他嗪(万爽力)治疗4周。观察治疗前后NYHA分级,并分别用超声测定左室射血分数(EF)和左室舒张末期内径(LVEDD)。结果治疗组心功能改善临床显效率(36.6%)和总有效率(85.4%)均较对照组(17.1%和61%)显著提高(均P<0.05),常规治疗组和治疗组治疗后LVEF均显著增加(P<0.05,P<0.01),LVEDD均显著缩小(P<0.05),且曲美他嗪治疗组较常规治疗组更加明显(P<0.05)。结论常规治疗缺血性心肌病心力衰竭基础上加用曲美他嗪,可以进一步改善患者心脏功能。
Objective This study aimed to observe the short-term efficacy of trimetazidine in the treatment of heart failure with ischemic cardiomyopathy (4 weeks). Methods This trial was a randomized, open, controlled clinical study. Eighty-two patients with ischemic cardiomyopathy and heart failure were randomly divided into routine treatment group (n = 41) and trimetazidine group (n = 41). Patients were given routine treatment and trimetazidine Shuangli) treatment for 4 weeks. NYHA grade was observed before and after treatment. Left ventricular ejection fraction (EF) and left ventricular end-diastolic diameter (LVEDD) were measured by ultrasound. Results The clinical effective rate (36.6%) and total effective rate (85.4%) in the treatment group were significantly higher than those in the control group (17.1% and 61% respectively) (all P <0.05) (P <0.05, P <0.01), LVEDD decreased significantly (P <0.05), and the trimetazidine treatment group was more obvious than the conventional treatment group (P <0.05). Conclusion Conventional treatment of ischemic cardiomyopathy combined with trimetazidine based on heart failure, can further improve the patient’s cardiac function.